This combination product further blurs the line between the two drug classes
Many expect this to evolve into one of the most significant pharmaceutical mass torts in recent history, particularly concerning diabetes and weight loss treatments
The two drugs have a different set of broader indications, with Zepbound also approved to treat sleep apnea in people with obesity, for example
These structural changes greatly increase the GLP-1 like peptide's half life (t 1/2 = 1 week) compared to endogenous GLP-1 (t 1/2 = 2 minutes)
This raises our awareness of never initiating SUs (Sulphonylurea) or Meglitides with once weekly GLP1RAs especially in naive T2DM patients
GLP-1 receptor agonists (like semaglutide, sold as Ozempic or Rybelsus) work by mimicking a gut hormone that helps regulate blood sugar, suppress appetite, and promote weight loss